{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lewy+Bodies+Disease",
    "query": {
      "condition": "Lewy Bodies Disease"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 273,
    "total_pages": 28,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lewy+Bodies+Disease&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T00:31:30.316Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03765918",
      "title": "Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Head and Neck Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab 200 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiotherapy 60 Gray",
          "type": "RADIATION"
        },
        {
          "name": "Radiotherapy 66 Gray",
          "type": "RADIATION"
        },
        {
          "name": "Radiotherapy 70 Gray",
          "type": "RADIATION"
        },
        {
          "name": "Cisplatin 100 mg/m^2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 714,
      "start_date": "2018-12-17",
      "completion_date": "2026-09-10",
      "has_results": true,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-11T00:31:30.316Z",
      "location_count": 68,
      "location_summary": "La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03765918"
    },
    {
      "nct_id": "NCT04002674",
      "title": "Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dementia With Lewy Bodies"
      ],
      "interventions": [
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "25 Years to 90 Years"
      },
      "enrollment_count": 43,
      "start_date": "2019-07-01",
      "completion_date": "2025-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-06-11T00:31:30.316Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04002674"
    },
    {
      "nct_id": "NCT04760860",
      "title": "Terazosin for Dementia With Lewy Bodies",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dementia With Lewy Bodies"
      ],
      "interventions": [
        {
          "name": "Terazosin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Qiang Zhang",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "0 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2027-10",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-06-11T00:31:30.316Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04760860"
    },
    {
      "nct_id": "NCT03360019",
      "title": "Accurate WiFi-Based Localization of Dementia Patients For Caregiver Support:",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dementia, Vascular",
        "Alzheimer Dementia",
        "Lewy Body Dementia With Behavioral Disturbance"
      ],
      "interventions": [
        {
          "name": "Activlink insole",
          "type": "DEVICE"
        },
        {
          "name": "Activlink Phone Application",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 13,
      "start_date": "2021-01-27",
      "completion_date": "2022-05-31",
      "has_results": true,
      "last_update_posted_date": "2023-05-17",
      "last_synced_at": "2026-06-11T00:31:30.316Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03360019"
    },
    {
      "nct_id": "NCT03374254",
      "title": "Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil [5-FU]",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2018-02-16",
      "completion_date": "2023-07-18",
      "has_results": true,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-06-11T00:31:30.316Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Aurora, Colorado • New Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03374254"
    },
    {
      "nct_id": "NCT05860127",
      "title": "Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dementia",
        "Cognitive Impairment, Mild",
        "Dementia, Vascular",
        "Dementia, Mixed",
        "Dementia With Lewy Bodies",
        "Dementia Frontal",
        "Dementia Moderate",
        "Dementia of Alzheimer Type",
        "Dementia, Mild"
      ],
      "interventions": [
        {
          "name": "Referral for Cognitive Stimulation Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "No change to Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Massachusetts, Amherst",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2023-04-10",
      "completion_date": "2025-06-12",
      "has_results": true,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-06-11T00:31:30.316Z",
      "location_count": 2,
      "location_summary": "Farmington, Connecticut • New Haven, Connecticut",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05860127"
    },
    {
      "nct_id": "NCT02834052",
      "title": "Pembrolizumab + Poly-ICLC in MRP Colon Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colon Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Poly-ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Asha Nayak",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2018-01-10",
      "completion_date": "2022-07-29",
      "has_results": true,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-06-11T00:31:30.316Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834052"
    },
    {
      "nct_id": "NCT04738487",
      "title": "Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Neoplasms",
        "Non-Small-Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab/Vibostolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1264,
      "start_date": "2021-04-07",
      "completion_date": "2026-01-27",
      "has_results": true,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-06-11T00:31:30.316Z",
      "location_count": 7,
      "location_summary": "Boca Raton, Florida • Peoria, Illinois • Springfield, Missouri + 4 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Mineola",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04738487"
    },
    {
      "nct_id": "NCT04148391",
      "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Mild Dementia",
        "Parkinson Disease",
        "Lewy Body Disease"
      ],
      "interventions": [
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "NYX-458",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aptinyx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 99,
      "start_date": "2019-11-14",
      "completion_date": "2022-12-30",
      "has_results": false,
      "last_update_posted_date": "2022-10-27",
      "last_synced_at": "2026-06-11T00:31:30.316Z",
      "location_count": 26,
      "location_summary": "Scottsdale, Arizona • Fresno, California • Simi Valley, California + 20 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Simi Valley",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04148391"
    },
    {
      "nct_id": "NCT06445465",
      "title": "Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Alpha-Synucleinopathy",
        "Parkinson's Disease",
        "Dementia With Lewy Bodies",
        "Multisystem Atrophy"
      ],
      "interventions": [
        {
          "name": "[18F]MNI-1216",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Invicro",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2020-12-24",
      "completion_date": "2024-11-26",
      "has_results": false,
      "last_update_posted_date": "2025-02-19",
      "last_synced_at": "2026-06-11T00:31:30.316Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06445465"
    }
  ]
}